Susannah Brock
Universitair Ziekenhuis Brussel(BE)Mathys (Netherlands)(NL)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial(2015)1,944 cited
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol(2018)246 cited
- → A Comparison of the Patterns of Migration and the Destinations of Homotopically Transplanted Neonatal Subventricular Zone Cells and Heterotopically Transplanted Telencephalic Ventricular Zone Cells(1996)98 cited
- → Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)(2022)73 cited
- → A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma(2022)43 cited
- → Muscarinic Receptors in Cell Lines from Ovarian Carcinoma: Negative Correlation with Survival of Patients(2002)39 cited
- → A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.(2022)28 cited
- → Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness(2018)26 cited
- → Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial(2022)24 cited